drugset / Trial / NCT00650897

Efficacy Study of Escitalopram for Depression in Patients With Diabetes

NCT00650897

Phase 4 Unknown 30 enrolled Sheba Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Patients with diabetes and major depression treated with Escitalopram might experience significant improvement in depression and anxiety scores; functional ability; diabetes-related self-care; and pain symptoms

Timeline

Start
2008-04
Primary completion
2009-06
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Escitalopram Small molecule 10 mg
Subject Escitalopram Small molecule 20 mg